世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

治療薬モニタリング市場：製品（消耗品、機器-免疫測定装置、クロマトグラフィー＆MS検出器、臨床化学分析装置）、技術、薬物クラス、エンドユーザー、地域別 - 2026年までの世界予測


Therapeutic Drug Monitoring Market by Product (Consumables, Equipment-Immunoassay Analyzers, Chromatography & MS Detectors, Clinical Chemistry Analyzers), Technology, Class of drugs, End user and Region - Global Forecast to 2026

治療薬モニタリングの世界市場は、2020年の16億米ドルから2026年には27億米ドルに達すると予測され、予測期間中のCAGRは9.4%となります。この市場の成長は、臓器移植手術数の増加、さまざまな治療分野でのTDMの利... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2022年2月1日 US$4,950
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら 		284 360 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

治療薬モニタリングの世界市場は、2020年の16億米ドルから2026年には27億米ドルに達すると予測され、予測期間中のCAGRは9.4%となります。この市場の成長は、臓器移植手術数の増加、さまざまな治療分野でのTDMの利用、精密医療への志向の高まり、TDM関連の研究開発への注力、免疫測定装置の技術的進歩が主な要因となっています。しかし、高額な設備投資の必要性や小規模病院がTDMサービスの提供に消極的であることが、同市場の成長を抑制する可能性がある。

"製品別では消耗品が予測期間中に最も高い成長を遂げる"
治療薬モニタリング市場は、製品に基づき、消耗品、機器-免疫測定分析器、クロマトグラフィー＆MS検出器、臨床化学分析器に区分されます。消耗品セグメントは、予測期間中に最も高いCAGRで成長すると予測されています。同市場の主な成長要因は、キットや試薬の繰り返し購入が必要なことと、世界的に免疫学的検査の実施件数が増加していることです。

"アジア太平洋地域は予測期間中に最も高いCAGRを記録すると推定される。"
本レポートでは、治療薬モニタリング市場を、北米、欧州、アジア太平洋、その他の地域（RoW）の4つの主要な地域セグメントに区分しています。アジア太平洋地域の市場は、予測期間中に最も高い成長率を記録すると予測されます。この市場の成長は、主に高齢者人口の増加（特に日本と中国）、日本における国民皆保険制度（移植および関連診断処置）、病気の早期発見と健康診断に関する意識向上への政府の取り組み、医療インフラの近代化と拡大のための中国とインドにおける政府支出の増加、慢性疾患の蔓延の増加によってもたらされます。

供給側一次面接の内訳、企業タイプ別、呼称別、地域別。

- 企業タイプ別Tier1 (32%) , Tier2 (44%) , Tier3 (24%)

- 職位別Cレベル(30%)、ディレクターレベル(34%)、その他(36%)

- 地域別北米(40%)、欧州(28%)、アジア太平洋(20%)、その他の地域(12%)


レポート掲載企業一覧

- アボット社（米国）
- サーモフィッシャーサイエンティフィック（米国）
- F・ホフマン・ラ・ロシュ社(スイス)
- シーメンス・ヘルスマイヤーズAG（ドイツ）
- ダナハーコーポレーション（米国）
- バイオ・ラッド・ラボラトリーズ（米国）
- ビオメリューSA（フランス）
- セラディアグSA（フランス）
- グリフォルスS.A.（スペイン）
- エクサジェン社(米国)
- R-Biopharm AG（ドイツ）
- ApDiaグループ（ベルギー）
- UTAK（米国）
- ランドックス・ラボラトリーズLtd.(アイルランド)
- アーク・ダイアグノスティックス株式会社(米国)
- BioTeZ Berlin-Buch GmbH（ドイツ）
- イーグル・バイオサイエンス社(米国)
- Jasem Laboratory Systems and Solutions（トルコ）
- アールトサイエンティフィック社（Aalto Scientific, Ltd.(米国)
- Immundiagnostik AG（ドイツ）
- 積水メディカル株式会社積水メディカル株式会社日本
- DiaSystem Scandinavia AB（スウェーデン）
- ケンブリッジ・ライフ・サイエンス社（英国）
- Chromsystems Instruments & Chemicals GmbH（ドイツ）
- BÜHLMANN Laboratories(スイス).

調査対象。
本レポートでは、治療薬モニタリング市場を製品別、地域別に調査しています。また、市場成長に影響を与える要因（促進要因、抑制要因、機会、課題など）を分析しています。利害関係者向けに市場の機会と課題を評価し、市場リーダー向けに競争環境の詳細を提供します。また、マイクロマーケットについては、その成長動向、展望、治療薬モニタリング市場全体への貢献度に関して調査しています。本レポートでは、5つの主要地域に関して、市場セグメントの収益を予測しています。


レポート購入の理由
本レポートは、以下のポイントに関する洞察を提供しています。

- 市場の浸透度。末梢血管用機器市場の上位25社が提供する治療薬モニタリング製品に関する包括的な情報。本レポートでは、末梢血管用デバイス市場を製品別、地域別に分析しています。

- 市場の発展。有利な新興市場に関する包括的な情報。このレポートでは、主要な地理的地域における様々な固定装置の市場を分析しています。

- 市場の多様化。治療薬モニタリング市場における未開拓の地域、最近の開発、投資に関する徹底的な情報提供

- 競合の評価。治療薬モニタリング市場における主要企業の市場シェアと戦略に関する詳細な評価

　

ページTOPに戻る


　

Summary

The global therapeutic drug monitoring market is projected to reach USD 2.7 billion by 2026 from USD 1.6 billion in 2020, at a CAGR of 9.4% during the forecast period. The growth of this market is majorly driven by the rising number of organ transplant procedures, the use of TDM across various therapeutic fields, the increasing preference for precision medicine, a growing focus on R&D related to TDM, and technological advancements in immunoassay instruments. However, the need for high capital investments and the reluctance of small hospitals to offer TDM services may restrain the growth of this market.

“Consumables in the product segment to witness the highest growth during the forecast period.”
Based on the product, the Therapeutic Drug Monitoring market is segmented into Consumables, Equipment-Immunoassay Analyzers, Chromatography & MS Detectors, Clinical Chemistry Analyzers. The Consumables segment is projected to grow at the highest CAGR during the forecast period. The major factors contributing to the growth of this market are the requirement of repeat purchase of kits and reagents, coupled with the increasing number of immunoassay tests being performed across the globe.

“Asia Pacific is estimated to register the highest CAGR during the forecast period.”
In this report, the Therapeutic Drug Monitoring market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). The market in Asia Pacific is projected to register the highest growth rate during the forecast period. The growth in this market is primarily driven by the rising geriatric population (especially in Japan and China), universal government healthcare coverage in Japan (for transplantation & related diagnostic procedures), government efforts to increase awareness about early disease detection and health check-ups, rising government expenditure in China and India to modernize and expand healthcare infrastructure, and the increasing prevalence of chronic diseases

Breakdown of supply-side primary interviews, by company type, designation, and region:

• By Company Type: Tier 1 (32%) , Tier 2 (44%), and Tier 3 (24%)

• By Designation: C-level (30%), Director-level (34%), and Others (36%)

• By Region: North America (40%), Europe (28%), AsiaPacific (20%), and Rest of the World(12%)


List of Companies Profiled in the Report

• Abbott (US)
• Thermo Fisher Scientific (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Siemens Healthineers AG (Germany)
• Danaher Corporation (US)
• Bio-Rad Laboratories (US)
• bioMérieux SA (France)
• Theradiag SA (France)
• Grifols S.A. (Spain)
• Exagen Inc. (US)
• R-Biopharm AG (Germany)
• ApDia Group (Belgium)
• UTAK (US)
• Randox Laboratories Ltd. (Ireland)
• ARK Diagnostics, Inc. (US)
• BioTeZ Berlin-Buch GmbH (Germany)
• Eagle Biosciences, Inc. (US)
• Jasem Laboratory Systems and Solutions (Turkey)
• Aalto Scientific, Ltd. (US)
• Immundiagnostik AG (Germany)
• Sekisui Medical Co. Ltd. (Japan)
• DiaSystem Scandinavia AB (Sweden)
• Cambridge Life Sciences Limited (UK)
• Chromsystems Instruments & Chemicals GmbH (Germany)
• BÜHLMANN Laboratories (Switzerland).

Research Coverage:
This report studies the Therapeutic Drug Monitoring market based on product, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total Therapeutic Drug Monitoring market. The report forecasts the revenue of the market segments with respect to five major regions.


Reasons to Buy the Report:
The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on Therapeutic Drug Monitoring products offered by the top 25 players in the peripheral vascular devices market. The report analyzes the peripheral vascular devices market by product, and region.

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various securement devices across key geographic regions.

• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the Therapeutic Drug Monitoring market

• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the Therapeutic Drug Monitoring market



ページTOPに戻る


Table of Contents

1 INTRODUCTION 40
1.1 OBJECTIVES OF THE STUDY 40
1.2 MARKET DEFINITION 40
1.2.1 INCLUSIONS & EXCLUSIONS 41
1.3 MARKET SCOPE 42
1.3.1 MARKETS COVERED 42
1.3.2 YEARS COVERED FOR THE STUDY 43
1.4 CURRENCY 43
1.5 LIMITATIONS 43
1.6 MARKET STAKEHOLDERS 44
1.7 SUMMARY OF CHANGES 44
2 RESEARCH METHODOLOGY 45
2.1 RESEARCH DATA 45
FIGURE 1 RESEARCH DESIGN 45
2.1.1 SECONDARY DATA 46
2.1.1.1 Secondary sources 47
2.1.2 PRIMARY DATA 47
FIGURE 2 PRIMARY SOURCES 47
2.1.2.1 Key data from primary sources 48
2.1.2.2 Key industry insights 49
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 50
2.2 MARKET SIZE ESTIMATION 50
FIGURE 4 REVENUE SHARE ANALYSIS ILLUSTRATION: THERMO FISHER SCIENTIFIC 51
FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 51
2.2.1 GROWTH FORECAST 52
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 52
FIGURE 7 TOP-DOWN APPROACH 53
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 54
FIGURE 8 DATA TRIANGULATION METHODOLOGY 54
2.4 MARKET SHARE ANALYSIS 55
2.5 ASSUMPTIONS FOR THE STUDY 55
2.6 INDICATORS AND ASSUMPTIONS AND THEIR IMPACT ON THE STUDY 56
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS 57
2.7 RISK ASSESSMENT 57
TABLE 1 RISK ASSESSMENT 57
2.8 COVID-19 HEALTH ASSESSMENT 58
2.9 COVID-19 ECONOMIC ASSESSMENT 58
2.10 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 59
3 EXECUTIVE SUMMARY 61
FIGURE 11 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2021 VS. 2026 (USD MILLION) 61
FIGURE 12 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2021 VS. 2026 (USD MILLION) 62
FIGURE 13 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 
2021 VS. 2026 (USD MILLION) 62
FIGURE 14 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2021 VS. 2026 (USD MILLION) 63
FIGURE 15 GEOGRAPHIC SNAPSHOT OF THE GLOBAL THERAPEUTIC 
DRUG MONITORING MARKET 63
4 PREMIUM INSIGHTS 65
4.1 THERAPEUTIC DRUG MONITORING MARKET OVERVIEW 65
FIGURE 16 RISING PREFERENCE FOR PRECISION MEDICINE TO DRIVE THE TDM MARKET 65
4.2 THERAPEUTIC DRUG MONITORING MARKET, BY TYPE 65
FIGURE 17 CONSUMABLE PRODUCTS TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2021 65
4.3 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG 66
FIGURE 18 ANTIEPILEPTIC DRUGS WILL DOMINATE THE ASIA PACIFIC MARKET IN 
2021-2026 66
4.4 GEOGRAPHIC SNAPSHOT OF THE THERAPEUTIC DRUG MONITORING MARKET 67
FIGURE 19 CHINA TO REGISTER THE HIGHEST CAGR OVER THE FORECAST PERIOD 67
5 MARKET OVERVIEW 68
5.1 INTRODUCTION 68
5.2 MARKET DYNAMICS 68
FIGURE 20 THERAPEUTIC DRUG MONITORING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 68
5.2.1 DRIVERS 69
5.2.1.1 Importance of TDM in organ transplant procedures 69
FIGURE 21 NUMBER OF DECEASED DONORS AND TRANSPLANTS IN THE UK (APRIL 1, 2017–MARCH 31, 2021) 69
5.2.1.2 Use of TDM across various therapeutic fields 70
TABLE 2 CLASSES OF DRUGS THAT REQUIRE MONITORING 70
5.2.1.3 Increasing preference for precision medicine 71
5.2.1.4 Growing focus on R&D related to TDM 71
FIGURE 22 NUMBER OF RESEARCH PUBLICATIONS ON THERAPEUTIC DRUG MONITORING (2015–2020) 71
5.2.1.5 Technological advancements 72
5.2.2 RESTRAINTS 72
5.2.2.1 Requirement of high capital investments 72
5.2.2.2 Reluctance of small hospitals to offer TDM services 72
5.2.3 OPPORTUNITIES 73
5.2.3.1 Increasing adoption in the treatment of autoimmune diseases 73
5.2.4 CHALLENGES 73
5.2.4.1 Alternatives to conventional TDM 73
5.2.4.2 Operational barriers faced in conducting TDM tests 74
5.3 COVID-19 IMPACT ON THE THERAPEUTIC DRUG MONITORING MARKET 74
5.4 RANGES/SCENARIOS 75
5.4.1 THERAPEUTIC DRUG MONITORING MARKET 75
FIGURE 23 PESSIMISTIC SCENARIO 75
FIGURE 24 OPTIMISTIC SCENARIO 75
FIGURE 25 REALISTIC SCENARIO 76
5.5 VALUE CHAIN ANALYSIS 76
FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE 77
5.6 SUPPLY CHAIN ANALYSIS 77
FIGURE 27 DIRECT DISTRIBUTION—THE PREFERRED STRATEGY FOR PROMINENT COMPANIES 79
5.7 PORTER’S FIVE FORCES ANALYSIS 80
5.7.1 THREAT OF NEW ENTRANTS 80
5.7.2 INTENSITY OF COMPETITIVE RIVALRY 80
5.7.3 BARGAINING POWER OF BUYERS 80
5.7.4 BARGAINING POWER OF SUPPLIERS 80
5.7.5 THREAT OF SUBSTITUTES 80
5.8 REGULATORY LANDSCAPE 81
5.9 PATENT ANALYSIS 82
5.10 PRICING ANALYSIS 83
TABLE 3 PRICE RANGE FOR THERAPEUTIC DRUG MONITORING 83
5.11 TRADE ANALYSIS 83
TABLE 4 IMPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2016–2020 (USD MILLION) 83
TABLE 5 EXPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN PHYSICAL 
AND CHEMICAL ANALYSIS, BY COUNTRY, BY COUNTRY, 
2016–2020 (USD MILLION) 83
5.12 ECOSYSTEM ANALYSIS 84
5.12.1 ROLE IN ECOSYSTEM 85
FIGURE 28 KEY PLAYERS IN THE THERAPEUTIC DRUG MONITORING 85
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 86
5.13.1 REVENUE SHIFT AND REVENUE POCKETS FOR THERAPEUTIC DRUG MONITORING MARKET 86
5.13.2 REVENUE SHIFT FOR THERAPEUTIC DRUG MONITORING 86
 
6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT 87
6.1 INTRODUCTION 88
TABLE 6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2016–2020 (USD MILLION) 88
TABLE 7 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2021–2026 (USD MILLION) 88
6.2 CONSUMABLES 88
6.2.1 REPEAT PURCHASE AND HIGH USAGE OF CONSUMABLES 
DRIVE MARKET GROWTH 88
TABLE 8 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 2016–2020 (USD MILLION) 89
TABLE 9 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 2021–2026 (USD MILLION) 89
6.3 EQUIPMENT 89
TABLE 10 DRUGS MONITORED USING ANALYTICAL EQUIPMENT 89
TABLE 11 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 
2016–2020 (USD MILLION) 90
TABLE 12 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 
2021–2026 (USD MILLION) 90
TABLE 13 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION, 
2016–2020 (USD MILLION) 91
TABLE 14 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION, 
2021–2026 (USD MILLION) 91
6.3.1 IMMUNOASSAY ANALYZERS 91
6.3.1.1 The high efficiency of immunoassay analyzers has ensured 
end-user demand 91
TABLE 15 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2016–2020 (USD MILLION) 92
TABLE 16 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2021–2026 (USD MILLION) 92
6.3.2 CHROMATOGRAPHY & MS DETECTORS 92
6.3.2.1 Technological advancements have propelled the growth of the segment 92
TABLE 17 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & 
MS DETECTORS, BY REGION, 2016–2020 (USD MILLION) 93
TABLE 18 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY & 
MS DETECTORS, BY REGION, 2021–2026 (USD MILLION) 93
6.3.3 CLINICAL CHEMISTRY ANALYZERS 93
6.3.3.1 Automation to raise preference for clinical chemistry analyzers 93
TABLE 19 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2016–2020 (USD MILLION) 94
TABLE 20 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2021–2026 (USD MILLION) 94
6.4 IMPACT OF COVID-19 ON THE TDM MARKET, BY PRODUCT 94
 
7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY 95
7.1 INTRODUCTION 96
TABLE 21 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2016–2020 (USD MILLION) 96
TABLE 22 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2021–2026 (USD MILLION) 96
7.2 IMMUNOASSAYS 96
TABLE 23 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 97
TABLE 24 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 97
TABLE 25 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION) 97
TABLE 26 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY REGION, 2021–2026 (USD MILLION) 98
7.2.1 CHEMILUMINESCENCE IMMUNOASSAYS 98
7.2.1.1 Rapid detection time and good specificity support the 
growth of the segment 98
TABLE 27 CLIA SYSTEMS AVAILABLE IN THE MARKET 98
TABLE 28 LIST OF COMPOUNDS ANALYZED BY CHEMILUMINESCENCE IMMUNOASSAY 99
TABLE 29 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY REGION, 
2016–2020 (USD MILLION) 100
TABLE 30 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY REGION, 
2021–2026 (USD MILLION) 100
7.2.2 FLUORESCENCE IMMUNOASSAYS 100
7.2.2.1 High operability and better sensitivity of FIAs to drive market growth 100
TABLE 31 LIST FOR COMPOUNDS ANALYZED BY FLUORESCENCE POLARIZATION IMMUNOASSAYS 101
TABLE 32 FLUORESCENCE IMMUNOASSAYS MARKET, BY REGION, 
2016–2020 (USD MILLION) 101
TABLE 33 FLUORESCENCE IMMUNOASSAYS MARKET, BY REGION, 
2021–2026 (USD MILLION) 102
7.2.3 COLORIMETRIC IMMUNOASSAYS 102
7.2.3.1 Demand for colorimetric immunoassays to decline due to the rising preference for advanced equipment 102
TABLE 34 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 
2016–2020 (USD MILLION) 102
TABLE 35 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 
2021–2026 (USD MILLION) 103
7.2.4 RADIOIMMUNOASSAYS 103
7.2.4.1 High sensitivity in drug detection applications supports the market for radioimmunoassays 103
TABLE 36 LIST OF COMPOUNDS ANALYZED BY RADIOIMMUNOASSAYS 103
TABLE 37 RADIOIMMUNOASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION) 104
TABLE 38 RADIOIMMUNOASSAYS MARKET, BY REGION, 2021–2026 (USD MILLION) 105
7.2.5 OTHER IMMUNOASSAYS 105
TABLE 39 OTHER IMMUNOASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION) 105
TABLE 40 OTHER IMMUNOASSAYS MARKET, BY REGION, 2021–2026 (USD MILLION) 106
7.3 CHROMATOGRAPHY-MS 106
TABLE 41 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, 
BY TYPE, 2016–2020 (USD MILLION) 106
TABLE 42 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, 
BY TYPE, 2021–2026 (USD MILLION) 107
7.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY 107
7.3.1.1 High accuracy supports the demand for LC-MS 107
TABLE 43 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2016–2020 (USD MILLION) 107
TABLE 44 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2021–2026 (USD MILLION) 108
7.3.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY 108
7.3.2.1 Drawbacks of GC-MS challenge market growth 108
TABLE 45 GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2016–2020 (USD MILLION) 108
TABLE 46 GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2021–2026 (USD MILLION) 109
8 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG 110
8.1 INTRODUCTION 111
TABLE 47 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 
2016–2020 (USD MILLION) 111
TABLE 48 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 
2021–2026 (USD MILLION) 111
8.2 ANTIEPILEPTIC DRUGS 112
8.2.1 HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE THE GROWTH OF THE SEGMENT 112
TABLE 49 LIMITATIONS OF TDM OF NEWER ANTIEPILEPTIC DRUGS 112
TABLE 50 ANTIEPILEPTIC DRUG MONITORING MARKET, BY REGION, 
2016–2020 (USD MILLION) 113
TABLE 51 ANTIEPILEPTIC DRUG MONITORING MARKET, BY REGION, 
2021–2026 (USD MILLION) 113
8.3 ANTIARRHYTHMIC DRUGS 113
8.3.1 INCREASING INCIDENCE OF HEART DISORDERS 
TO SUPPORT SEGMENT GROWTH 113
TABLE 52 ANTIARRHYTHMIC DRUG MONITORING MARKET, BY REGION, 
2016–2020 (USD MILLION) 114
TABLE 53 ANTIARRHYTHMIC DRUG MONITORING MARKET, BY REGION, 
2021–2026 (USD MILLION) 114
8.4 IMMUNOSUPPRESSANT DRUGS 114
8.4.1 IMMUNOSUPPRESSANT DEMAND HAS RISEN DUE TO AN INCREASE IN ORGAN TRANSPLANTATION PROCEDURES 114
TABLE 54 IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY REGION, 
2016–2020 (USD MILLION) 115
TABLE 55 IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY REGION, 
2021–2026 (USD MILLION) 115
8.5 ANTIBIOTIC DRUGS 116
8.5.1 TECHNOLOGICAL ADVANCEMENTS TO PROPEL THE DEMAND FOR ANTIBIOTIC DRUG MONITORING 116
TABLE 56 ANTIBIOTIC DRUG MONITORING MARKET, BY REGION, 
2016–2020 (USD MILLION) 116
TABLE 57 ANTIBIOTIC DRUG MONITORING MARKET, BY REGION, 
2021–2026 (USD MILLION) 116
8.6 BRONCHODILATOR DRUGS 117
8.6.1 INCREASING PREVALENCE OF RESPIRATORY DISEASES WILL ENSURE DEMAND FOR BRONCHODILATOR DRUG MONITORING 117
TABLE 58 BRONCHODILATOR DRUG MONITORING MARKET, BY REGION, 
2016–2020 (USD MILLION) 117
TABLE 59 BRONCHODILATOR DRUG MONITORING MARKET, BY REGION, 
2021–2026 (USD MILLION) 117
8.7 PSYCHOACTIVE DRUGS 118
8.7.1 RISING CASES OF MENTAL ILLNESS TO DRIVE MARKET GROWTH 118
TABLE 60 PSYCHOACTIVE DRUG MONITORING MARKET, BY REGION,
 2016–2020 (USD MILLION) 118
TABLE 61 PSYCHOACTIVE DRUG MONITORING MARKET, BY REGION, 
2021–2026 (USD MILLION) 118
8.8 OTHER DRUGS 119
TABLE 62 OTHER DRUG MONITORING MARKET, BY REGION, 
2016–2020 (USD MILLION) 119
TABLE 63 OTHER DRUG MONITORING MARKET, BY REGION, 
2021–2026 (USD MILLION) 119
8.9 IMPACT OF COVID-19 ON THE TDM MARKET, BY CLASS OF DRUG 120
9 THERAPEUTIC DRUG MONITORING MARKET, BY END USER 121
9.1 INTRODUCTION 122
TABLE 64 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2016–2020 (USD MILLION) 122
TABLE 65 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2021–2026 (USD MILLION) 122
9.2 HOSPITAL LABORATORIES 123
9.2.1 HOSPITAL LABS HOLD THE LARGEST SHARE OF THE END-USER MARKET 123
TABLE 66 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2016–2020 (USD MILLION) 123
TABLE 67 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2021–2026 (USD MILLION) 123
9.3 COMMERCIAL & PRIVATE LABORATORIES 124
9.3.1 EXTENSIVE TEST MENUS OF COMMERCIAL & PRIVATE LABS SUPPORT DEMAND FOR THEIR SERVICES 124
TABLE 68 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2016–2020 (USD MILLION) 124
TABLE 69 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2021–2026 (USD MILLION) 124
9.4 OTHER END USERS 125
TABLE 70 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, 
BY REGION, 2016–2020 (USD MILLION) 125
TABLE 71 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, 
BY REGION, 2021–2026 (USD MILLION) 125
9.5 IMPACT OF COVID-19 ON THE TDM MARKET, BY END USER 125
10 THERAPEUTIC DRUG MONITORING MARKET, BY REGION 126
10.1 INTRODUCTION 127
TABLE 72 THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 
2016–2020 (USD MILLION) 127
TABLE 73 THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 
2021–2026 (USD MILLION) 127
10.2 NORTH AMERICA 128
FIGURE 29 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARK ET SNAPSHOT 129
TABLE 74 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2016–2020 (USD MILLION) 130
TABLE 75 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 130
TABLE 76 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION) 130
TABLE 77 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION) 130
TABLE 78 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2016–2020 (USD MILLION) 131
TABLE 79 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2021–2026 (USD MILLION) 131
TABLE 80 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION) 131
TABLE 81 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 132
TABLE 82 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 132
TABLE 83 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 132
TABLE 84 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 133
TABLE 85 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 133
TABLE 86 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 133
TABLE 87 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 134
TABLE 88 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION) 134
TABLE 89 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION) 134
10.2.1 US 135
10.2.1.1 Awareness regarding precision medicine to propel the 
TDM market in the US 135
TABLE 90 NUMBER OF TESTS COVERED BY MEDICARE FOR EACH DRUG CLASS 135
TABLE 91 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2016–2020 (USD MILLION) 136
TABLE 92 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2021–2026 (USD MILLION) 136
TABLE 93 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2016–2020 (USD MILLION) 136
TABLE 94 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2021–2026 (USD MILLION) 136
TABLE 95 US: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 137
TABLE 96 US: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 137
TABLE 97 US: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 137
TABLE 98 US: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 138
TABLE 99 US: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 
2016–2020 (USD MILLION) 138
TABLE 100 US: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 
2021–2026 (USD MILLION) 138
TABLE 101 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2016–2020 (USD MILLION) 139
TABLE 102 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2021–2026 (USD MILLION) 139
10.2.2 CANADA 139
10.2.2.1 Availability of funding for research to offer growth opportunities in the Canadian market 139
TABLE 103 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2016–2020 (USD MILLION) 140
TABLE 104 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2021–2026 (USD MILLION) 140
TABLE 105 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION) 141
TABLE 106 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 141
TABLE 107 CANADA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
 BY TYPE, 2016–2020 (USD MILLION) 141
TABLE 108 CANADA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, 
BY TYPE, 2021–2026 (USD MILLION) 142
TABLE 109 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 142
TABLE 110 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 142
TABLE 111 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 143
TABLE 112 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 143
TABLE 113 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2016–2020 (USD MILLION) 143
TABLE 114 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2021–2026 (USD MILLION) 144
10.3 EUROPE 144
TABLE 115 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 
2016–2020 (USD MILLION) 144
TABLE 116 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 
2021–2026 (USD MILLION) 145
TABLE 117 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2016–2020 (USD MILLION) 145
TABLE 118 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2021–2026 (USD MILLION) 145
TABLE 119 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2016–2020 (USD MILLION) 146
TABLE 120 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2021–2026 (USD MILLION) 146
TABLE 121 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION) 146
TABLE 122 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 147
TABLE 123 EUROPE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, 
BY TYPE, 2016–2020 (USD MILLION) 147
TABLE 124 EUROPE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, 
BY TYPE, 2021–2026 (USD MILLION) 147
TABLE 125 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 148
TABLE 126 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 148
TABLE 127 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 148
TABLE 128 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 149
TABLE 129 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2016–2020 (USD MILLION) 149
TABLE 130 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2021–2026 (USD MILLION) 149
10.3.1 GERMANY 150
10.3.1.1 Prevalence of chronic medical conditions such as cancer and diabetes will support market growth in Germany 150
TABLE 131 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2016–2020 (USD MILLION) 150
TABLE 132 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2021–2026 (USD MILLION) 151
TABLE 133 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION) 151
TABLE 134 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 151
TABLE 135 GERMANY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, 
BY TYPE, 2016–2020 (USD MILLION) 152
TABLE 136 GERMANY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, 
BY TYPE, 2021–2026 (USD MILLION) 152
TABLE 137 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 152
TABLE 138 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 153
TABLE 139 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 153
TABLE 140 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 153
TABLE 141 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION) 154
TABLE 142 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION) 154
10.3.2 ITALY 154
10.3.2.1 Rising incidences of cancer to drive demand for TDM in Italy 154
TABLE 143 ITALY: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025 155
TABLE 144 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2016–2020 (USD MILLION) 155
TABLE 145 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2021–2026 (USD MILLION) 155
TABLE 146 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2016–2020 (USD MILLION) 156
TABLE 147 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2021–2026 (USD MILLION) 156
TABLE 148 ITALY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 156
TABLE 149 ITALY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 157
TABLE 150 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 157
TABLE 151 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 157
TABLE 152 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 158
TABLE 153 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 158
TABLE 154 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2016–2020 (USD MILLION) 158
TABLE 155 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2021–2026 (USD MILLION) 159
10.3.3 FRANCE 159
10.3.3.1 Awareness regarding the benefits of TDM to accelerate its demand across various therapeutic applications 159
TABLE 156 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2016–2020 (USD MILLION) 160
TABLE 157 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
 2021–2026 (USD MILLION) 160
TABLE 158 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION) 160
TABLE 159 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 160
TABLE 160 FRANCE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, 
BY TYPE, 2016–2020 (USD MILLION) 161
TABLE 161 FRANCE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, 
BY TYPE, 2021–2026 (USD MILLION) 161
TABLE 162 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 161
TABLE 163 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 162
TABLE 164 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 162
TABLE 165 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 162
TABLE 166 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2016–2020 (USD MILLION) 163
TABLE 167 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2021–2026 (USD MILLION) 163
10.3.4 SPAIN 163
10.3.4.1 Adoption of technologically advanced immunoassays has boosted the market in Spain 163
TABLE 168 SPAIN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025 164
TABLE 169 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2016–2020 (USD MILLION) 164
TABLE 170 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2021–2026 (USD MILLION) 164
TABLE 171 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2016–2020 (USD MILLION) 165
TABLE 172 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2021–2026 (USD MILLION) 165
TABLE 173 SPAIN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, 
BY TYPE, 2016–2020 (USD MILLION) 165
TABLE 174 SPAIN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, 
BY TYPE, 2021–2026 (USD MILLION) 166
TABLE 175 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 166
TABLE 176 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 166
TABLE 177 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 167
TABLE 178 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 167
TABLE 179 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2016–2020 (USD MILLION) 168
TABLE 180 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2021–2026 (USD MILLION) 168
10.3.5 UK 168
10.3.5.1 Increasing cases of chronic diseases to drive the growth of the TDM market 168
TABLE 181 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2016–2020 (USD MILLION) 169
TABLE 182 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2021–2026 (USD MILLION) 169
TABLE 183 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2016–2020 (USD MILLION) 170
TABLE 184 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2021–2026 (USD MILLION) 170
TABLE 185 UK: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 170
TABLE 186 UK: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 171
TABLE 187 UK: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 171
TABLE 188 UK: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 171
TABLE 189 UK: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 
2016–2020 (USD MILLION) 172
TABLE 190 UK: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 
2021–2026 (USD MILLION) 172
TABLE 191 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2016–2020 (USD MILLION) 172
TABLE 192 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2021–2026 (USD MILLION) 173
10.3.6 REST OF EUROPE 173
TABLE 193 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2016–2020 (USD MILLION) 173
TABLE 194 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2021–2026 (USD MILLION) 173
TABLE 195 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2016–2020 (USD MILLION) 174
TABLE 196 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2021–2026 (USD MILLION) 174
TABLE 197 ROE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 174
TABLE 198 ROE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 175
TABLE 199 ROE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 175
TABLE 200 ROE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 175
TABLE 201 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 176
TABLE 202 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 176
TABLE 203 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2016–2020 (USD MILLION) 177
TABLE 204 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2021–2026 (USD MILLION) 177
10.4 ASIA PACIFIC 177
FIGURE 30 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT 178
TABLE 205 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2016–2020 (USD MILLION) 179
TABLE 206 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 179
TABLE 207 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION) 179
TABLE 208 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION) 180
TABLE 209 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, 
BY TYPE, 2016–2020 (USD MILLION) 180
TABLE 210 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET,
BY TYPE, 2021–2026 (USD MILLION) 180
TABLE 211 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION) 181
TABLE 212 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 181
TABLE 213 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 181
TABLE 214 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 182
TABLE 215 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 182
TABLE 216 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 182
TABLE 217 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 183
TABLE 218 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 183
TABLE 219 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION) 184
TABLE 220 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION) 184
10.4.1 JAPAN 184
10.4.1.1 Japan holds the largest share of the APAC market for therapeutic drug monitoring 184
TABLE 221 JAPAN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025 185
TABLE 222 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2016–2020 (USD MILLION) 185
TABLE 223 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2021–2026 (USD MILLION) 185
TABLE 224 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2016–2020 (USD MILLION) 186
TABLE 225 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2021–2026 (USD MILLION) 186
TABLE 226 JAPAN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, 
BY TYPE, 2016–2020 (USD MILLION) 186
TABLE 227 JAPAN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, 
BY TYPE, 2021–2026 (USD MILLION) 187
TABLE 228 JAPAN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 187
TABLE 229 JAPAN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 187
TABLE 230 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 188
TABLE 231 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 188
TABLE 232 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2016–2020 (USD MILLION) 189
TABLE 233 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2021–2026 (USD MILLION) 189
10.4.2 CHINA 189
10.4.2.1 Rising number of organ transplants in the country will drive the growth of the TDM market 189
TABLE 234 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2016–2020 (USD MILLION) 190
TABLE 235 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2021–2026 (USD MILLION) 190
TABLE 236 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2016–2020 (USD MILLION) 190
TABLE 237 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2021–2026 (USD MILLION) 190
TABLE 238 CHINA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, 
BY TYPE, 2016–2020 (USD MILLION) 191
TABLE 239 CHINA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, 
BY TYPE, 2021–2026 (USD MILLION) 191
TABLE 240 CHINA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 191
TABLE 241 CHINA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 192
TABLE 242 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 192
TABLE 243 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 192
TABLE 244 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2016–2020 (USD MILLION) 193
TABLE 245 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2021–2026 (USD MILLION) 193
10.4.3 INDIA 193
10.4.3.1 Rising incidence of cancer to propel market growth 193
TABLE 246 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2016–2020 (USD MILLION) 194
TABLE 247 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2021–2026 (USD MILLION) 194
TABLE 248 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2016–2020 (USD MILLION) 194
TABLE 249 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2021–2026 (USD MILLION) 195
TABLE 250 INDIA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, 
BY TYPE, 2016–2020 (USD MILLION) 195
TABLE 251 INDIA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, 
BY TYPE, 2021–2026 (USD MILLION) 195
TABLE 252 INDIA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 196
TABLE 253 INDIA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 196
TABLE 254 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 196
TABLE 255 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 197
TABLE 256 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2016–2020 (USD MILLION) 197
TABLE 257 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2021–2026 (USD MILLION) 197
10.4.4 ROAPAC 198
TABLE 258 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2016–2020 (USD MILLION) 198
TABLE 259 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2021–2026 (USD MILLION) 199
TABLE 260 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION) 199
TABLE 261 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 199
TABLE 262 ROAPAC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, 
BY TYPE, 2016–2020 (USD MILLION) 200
TABLE 263 ROAPAC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, 
BY TYPE, 2021–2026 (USD MILLION) 200
TABLE 264 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 200
TABLE 265 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 201
TABLE 266 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 201
TABLE 267 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 201
TABLE 268 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2016–2020 (USD MILLION) 202
TABLE 269 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2021–2026 (USD MILLION) 202
10.5 REST OF THE WORLD 202
10.5.1 ROW ACCOUNTS FOR THE SMALLEST SHARE OF THE OVERALL MARKET BUT IS EXPECTED TO SEE HIGH GROWTH 202
TABLE 270 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2016–2020 (USD MILLION) 203
TABLE 271 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 
2021–2026 (USD MILLION) 203
TABLE 272 ROW: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2016–2020 (USD MILLION) 204
TABLE 273 ROW: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2021–2026 (USD MILLION) 204
TABLE 274 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2016–2020 (USD MILLION) 204
TABLE 275 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 
2021–2026 (USD MILLION) 205
TABLE 276 ROW: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 205
TABLE 277 ROW: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 205
TABLE 278 ROW: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 206
TABLE 279 ROW: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 206
TABLE 280 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 206
TABLE 281 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 207
TABLE 282 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2016–2020 (USD MILLION) 207
TABLE 283 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 
2021–2026 (USD MILLION) 207
11 COMPETITIVE LANDSCAPE 208
11.1 OVERVIEW 208
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 208
TABLE 284 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN THE THERAPEUTIC DRUG MONITORING MARKET 208
11.3 MARKET SHARE ANALYSIS 210
TABLE 285 THERAPEUTIC DRUG MONITORING MARKET: DEGREE OF COMPETITION 210
11.4 COMPANY EVALUATION QUADRANT 211
11.4.1 STARS 211
11.4.2 EMERGING LEADERS 211
11.4.3 PERVASIVE PLAYERS 211
11.4.4 PARTICIPANTS 211
FIGURE 31 COMPANY EVALUATION QUADRANT: THERAPEUTIC 
DRUG MONITORING MARKET 212
11.5 COMPANY EVALUATION QUADRANT FOR SMES/START-UPS 213
11.5.1 PROGRESSIVE COMPANIES 213
11.5.2 STARTING BLOCKS 213
11.5.3 RESPONSIVE COMPANIES 213
11.5.4 DYNAMIC COMPANIES 213
FIGURE 32 COMPANY EVALUATION MATRIX FOR SMES/START-UPS: 
THERAPEUTIC DRUG MONITORING MARKET 214
11.6 COMPANY FOOTPRINT ANALYSIS 215
TABLE 286 COMPANY FOOTPRINT 215
TABLE 287 COMPANY REGIONAL FOOTPRINT 216
TABLE 288 COMPANY PRODUCT FOOTPRINT 217
11.7 COMPETITIVE SCENARIO 218
11.7.1 PRODUCT APPROVALS 218
TABLE 289 KEY PRODUCT APPROVALS 218
11.7.2 PRODUCT LAUNCHES 218
TABLE 290 KEY PRODUCT LAUNCHES 218
11.7.3 AGREEMENTS 219
TABLE 291 KEY AGREEMENTS 219
11.7.4 ACQUISITIONS 219
TABLE 292 KEY ACQUISITIONS 219
11.7.5 OTHER DEVELOPMENTS 220
TABLE 293 KEY EXPANSIONS 220
12 COMPANY PROFILES 221
12.1 KEY PLAYERS 221
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 ABBOTT 221
TABLE 294 ABBOTT: BUSINESS OVERVIEW 221
FIGURE 33 ABBOTT: COMPANY SNAPSHOT (2020) 222
12.1.2 THERMO FISHER SCIENTIFIC 225
TABLE 295 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 225
FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020) 226
12.1.3 F. HOFFMANN-LA ROCHE 230
TABLE 296 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW 230
FIGURE 35 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2020) 231
12.1.4 SIEMENS HEALTHINEERS AG 235
TABLE 297 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 235
FIGURE 36 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2020) 236
12.1.5 DANAHER CORPORATION 241
TABLE 298 DANAHER CORPORATION: BUSINESS OVERVIEW 241
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 242
12.1.6 BIO-RAD LABORATORIES 245
TABLE 299 BIO-RAD LABORATORIES: BUSINESS OVERVIEW 245
FIGURE 38 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020) 246
12.1.7 BIOMÉRIEUX SA 251
TABLE 300 BIOMÉRIEUX SA: BUSINESS OVERVIEW 251
FIGURE 39 BIOMÉRIEUX SA.: COMPANY SNAPSHOT (2020) 252
12.1.8 THERADIAG SA. 253
TABLE 301 THERADIAG SA.: BUSINESS OVERVIEW 253
FIGURE 40 THERADIAG SA.: COMPANY SNAPSHOT (2020) 254
12.1.9 GRIFOLS S.A. 256
TABLE 302 GRIFOLS S.A.: BUSINESS OVERVIEW 256
FIGURE 41 GRIFOLS S.A.: COMPANY SNAPSHOT (2020) 257
12.1.10 EXAGEN INC. 260
TABLE 303 EXAGEN INC.: BUSINESS OVERVIEW 260
FIGURE 42 EXAGEN INC.: COMPANY SNAPSHOT (2020) 260
12.1.11 R-BIOPHARM AG 262
TABLE 304 R-BIOPHARM AG: BUSINESS OVERVIEW 262
12.1.12 APDIA GROUP 264
TABLE 305 APDIA: BUSINESS OVERVIEW 264
12.1.13 BIOTEZ BERLIN BUCH GMBH 265
TABLE 306 BIOTEZ BERLIN BUCH GMBH: BUSINESS OVERVIEW 265
12.1.14 EAGLE BIOSCIENCES, INC. 266
TABLE 307 EAGLE BIOSCIENCES, INC.: BUSINESS OVERVIEW 266
12.1.15 JASEM LABORATORY SYSTEMS AND SOLUTIONS 270
TABLE 308 JASEM LABORATORY SYSTEMS AND SOLUTIONS: BUSINESS OVERVIEW 270
12.1.16 AALTO SCIENTIFIC, LTD. 271
TABLE 309 AALTO SCIENTIFIC, LTD: BUSINESS OVERVIEW 271
12.1.17 IMMUNDIAGNOSTIK AG. 272
TABLE 310 IMMUNDIAGNOSTIK AG: BUSINESS OVERVIEW 272
12.1.18 UTAK 273
TABLE 311 UTAK: BUSINESS OVERVIEW 273
12.1.19 SEKISUI MEDICAL CO., LTD. 275
TABLE 312 SEKISUI MEDICAL CO., LTD.: BUSINESS OVERVIEW 275
12.1.20 RANDOX LABORATORIES LTD. 277
TABLE 313 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW 277
12.1.21 DIASYSTEM SCANDINAVIA AB 280
TABLE 314 DIASYSTEM SCANDINAVIA AB: BUSINESS OVERVIEW 280
12.1.22 CAMBRIDGE LIFE SCIENCES LIMITED 281
TABLE 315 CAMBRIDGE LIFE SCIENCES LIMITED: BUSINESS OVERVIEW 281
12.1.23 ARK DIAGNOSTICS, INC. 282
TABLE 316 ARK DIAGNOSTICS, INC.: BUSINESS OVERVIEW 282
12.1.24 HROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH 286
TABLE 317 CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH: 
BUSINESS OVERVIEW 286
12.1.25 BÜHLMANN LABORATORIES 289
TABLE 318 BÜHLMANN LABORATORIES: BUSINESS OVERVIEW 289
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 291
13.1 INSIGHTS FROM INDUSTRY EXPERTS 291
13.2 DISCUSSION GUIDE 292
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 295
13.4 AVAILABLE CUSTOMIZATIONS 297
13.5 RELATED REPORTS 297
13.6 AUTHOR DETAILS 298

 

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（その他）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（consumables）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/09/24　10:26

144.74 円

161.12 円

195.86 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.